Inhibrx Q1 2023 Earnings Report $14.12 -0.20 (-1.40%) As of 03/28/2025 04:00 PM Eastern Earnings HistoryForecast Inhibrx EPS ResultsActual EPS-$1.12Consensus EPS -$0.84Beat/MissMissed by -$0.28One Year Ago EPSN/AInhibrx Revenue ResultsActual Revenue$0.02 millionExpected Revenue$0.30 millionBeat/MissMissed by -$280.00 thousandYoY Revenue GrowthN/AInhibrx Announcement DetailsQuarterQ1 2023Date5/8/2023TimeN/AConference Call ResourcesINBX Earnings History Remove Ads Inhibrx Earnings HeadlinesInhibrx Biosciences Full Year 2024 Earnings: Beats ExpectationsMarch 19, 2025 | finance.yahoo.comInhibrx Biosciences, Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 18, 2025 | finanznachrichten.deTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.March 29, 2025 | Porter & Company (Ad)Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial ResultsMarch 17, 2025 | prnewswire.comInhibrx's SWOT analysis: oncology biotech stock faces pivotal year aheadJanuary 22, 2025 | msn.comInhibrx Biosciences Inc (INBX) Gets a Hold from JMP SecuritiesJanuary 22, 2025 | markets.businessinsider.comSee More Inhibrx Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Inhibrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibrx and other key companies, straight to your email. Email Address About InhibrxInhibrx (NASDAQ:INBX), a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.View Inhibrx ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio?Analysts Lift Archer Aviation Stock Despite Earnings Miss Upcoming Earnings Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025)Progressive (4/11/2025)Wells Fargo & Company (4/11/2025)Interactive Brokers Group (4/15/2025)Bank of America (4/15/2025)Citigroup (4/15/2025)Johnson & Johnson (4/15/2025)Morgan Stanley (4/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
